🔗 Share this article

While the US proceeds with sweeping changes to its vaccine schedules, an unexpected name has surfaced in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning COVID-19 shots in the pandemic and has zeroed in on potential deaths after Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Health officials had intended to announce radical changes to the pediatric immunization program recently, aligning the US with the Danish vaccine program, according to reports – a significant shift that would place the US at odds with much of the international standard with insufficient data for benefit. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth person to head the office this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood shot schedules in the US so as to align more like Denmark, a society with universal health coverage and a population approximately the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

Dr. Høeg has no apparent background in drug development, regulation or management, which has been customary for previous directors of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who led the center have had.”

The drug center has an vast portfolio at the FDA, she stated.

“Everybody just pays attention on the novel medication approvals, but the generic drug division approves a multitude of generic medications. There is also a biosimilars division, over-the-counter program and other areas, and every single one have to be managed,” she explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a significant management element to the role, which manages over 5,000 employees. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Response and Contentious Programs

When asked about concerns about Høeg’s credentials and whether this selection signifies increased cooperation among agency officials on vaccines, a spokesperson said that the “questions are based on incorrect presumptions”.

“Her experience aligns with the duties of her position,” the representative explained, pointing to the time Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed rapid medication authorization process that allegedly troubled her predecessors. “By what process are these medications being chosen for this fast-track system? Who takes the choices?” Dr. Howard said. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he said, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Public History on Vaccines

With immunizations, Høeg has a clearer, if concerning, past, critics said. She published a research paper using non-validated crowd-sourced reports to assess the rate of heart inflammation after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the current administration encompassed altering rules for novel immunizations and discontinuing “unnecessary” immunizations, she said following the vote on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of preventing young men from receiving COVID-19 vaccines.

“She’s an complete true believer who commences with her beliefs and reverse-engineers to accommodate the evidence in a highly misleading, untruthful fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|